Literature DB >> 22231867

Does fingolimod in multiple sclerosis patients cause macular edema?

Kiran Turaka1, Joseph Shepard Bryan.   

Abstract

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system and is the common cause of optic neuritis. Fingolimod, an immunosuppressive agent, is used in MS to prevent acute exacerbations. We report a case of relapsing-remitting MS treated with fingolimod. The patient presented with an acute decrease in vision in the left eye. Eye examination showed clinical macular edema (ME) in the left eye, which was confirmed on fluorescein angiogram and optical coherence tomography (OCT). After discontinuation of fingolimod and treatment with topical corticosteroid medication, there was complete resolution of the ME. The ME as a side-effect of fingolimod is reversible after discontinuing, which was seen on OCT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231867     DOI: 10.1007/s00415-011-6367-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  9 in total

Review 1.  Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.

Authors:  Alison Huggins; Robert C Sergott
Journal:  Curr Opin Ophthalmol       Date:  2011-11       Impact factor: 3.761

Review 2.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

Review 3.  Current disease-modifying treatment of multiple sclerosis.

Authors:  Joy Derwenskus
Journal:  Mt Sinai J Med       Date:  2011 Mar-Apr

4.  Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient.

Authors:  Georges Saab; Arghavan Almony; Kevin J Blinder; Rebecca Schuessler; Daniel C Brennan
Journal:  Arch Ophthalmol       Date:  2008-01

5.  Trial watch: Phase III promise for oral multiple sclerosis therapy.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

6.  Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.

Authors:  G Comi; P O'Connor; X Montalban; J Antel; E-W Radue; G Karlsson; H Pohlmann; S Aradhye; L Kappos
Journal:  Mult Scler       Date:  2009-12-22       Impact factor: 6.312

Review 7.  Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.

Authors:  E Ann Yeh; B Weinstock-Guttman
Journal:  Adv Ther       Date:  2011-03-07       Impact factor: 3.845

8.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

Review 9.  Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Authors:  Jerold Chun; Hans-Peter Hartung
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

  9 in total
  13 in total

1.  Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis.

Authors:  Niannian Ji; Animesh Somanaboeina; Aakanksha Dixit; Kazuyuki Kawamura; Neil J Hayward; Christopher Self; Gary L Olson; Thomas G Forsthuber
Journal:  J Immunol       Date:  2013-10-11       Impact factor: 5.422

2.  Postoperative cystoid macular oedema in a patient on fingolimod.

Authors:  Jennifer Chen-Chia Fan Gaskin; Michael Coote
Journal:  BMJ Case Rep       Date:  2015-05-12

Review 3.  Drug-induced macular edema.

Authors:  Olga E Makri; Ilias Georgalas; Constantine D Georgakopoulos
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

Review 4.  Fingolimod: therapeutic mechanisms and ocular adverse effects.

Authors:  P Mandal; A Gupta; W Fusi-Rubiano; P A Keane; Y Yang
Journal:  Eye (Lond)       Date:  2016-11-25       Impact factor: 3.775

5.  Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis.

Authors:  Lei Liu; Fiona Cuthbertson
Journal:  Case Rep Med       Date:  2012-09-13

6.  Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?

Authors:  Anja Mähler; Silvia Mandel; Mario Lorenz; Urs Ruegg; Erich E Wanker; Michael Boschmann; Friedemann Paul
Journal:  EPMA J       Date:  2013-02-18       Impact factor: 6.543

7.  Continuing fingolimod after development of macular edema: A case report.

Authors:  Vivien Li; Jack Kane; Helen H L Chan; Anthony J Hall; Helmut Butzkueven
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-05-15

8.  Infectious and noninfectious granulomatosis in patient with multiple sclerosis: diagnostic dilemmas and followup.

Authors:  Jelena Paovic; Predrag Paovic; Vojislav Sredovic
Journal:  Case Reports Immunol       Date:  2014-02-17

9.  Fingolimod Associated Bilateral Cystoid Macular Edema-Wait and See?

Authors:  Refik Pul; Alma Osmanovic; Holger Schmalstieg; Amelie Pielen; Kaweh Pars; Philipp Schwenkenbecher; Kurt Wolfram Sühs; Özlem Yildiz; Benedikt Frank; Martin Stangel; Thomas Skripuletz
Journal:  Int J Mol Sci       Date:  2016-12-14       Impact factor: 5.923

10.  Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.

Authors:  Hisanao Akiyama; Yu Suzuki; Daisuke Hara; Kensuke Shinohara; Hana Ogura; Masashi Akamatsu; Yasuhiro Hasegawa
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.